{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:37:24Z","timestamp":1777412244217,"version":"3.51.4"},"reference-count":37,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with relapsed or refractory (R\/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R\/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82\u00a0patients with R\/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3\/4 adverse events that were mainly hematologic. BBv is highly active in patients with R\/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008524","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T19:57:13Z","timestamp":1670443033000},"page":"5733-5742","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Salvage therapy with brentuximab-vedotin and bendamustine for\u00a0patients with R\/R PTCL: a retrospective study from the LYSA group"],"prefix":"10.1182","volume":"7","author":[{"given":"Raphaelle","family":"Aubrais","sequence":"first","affiliation":[{"name":"1Department of Hematology, Bordeaux University Hospital, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Bordeaux University Hospital, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Chartier","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The Lymphoma Academic Research Organization, Pierre-B\u00e9nite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Montpellier University Hospital, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Banos","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Centre Hospitalier de la Cote Basque Bayonne, Bayonne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"5Department of Hematology, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-625X","authenticated-orcid":false,"given":"David","family":"Sibon","sequence":"additional","affiliation":[{"name":"6Department of Hematology, H\u00f4pital Necker-Enfants maladies, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-4808","authenticated-orcid":false,"given":"Jean Marc","family":"Schiano","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Institut Paoli Calmettes, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Nice University Hospital, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier du Mans, Le-Mans, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-1825","authenticated-orcid":false,"given":"Ronan","family":"Le Calloch","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Centre Hospitalier de Cornouaille, Quimper, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Bellal","sequence":"additional","affiliation":[{"name":"11Hematology Institute, University Hospital, Normandy University, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Delapierre","sequence":"additional","affiliation":[{"name":"11Hematology Institute, University Hospital, Normandy University, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Daguindau","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Centre Hospitalier Annecy Genevois, Annecy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hopital Saint-Vincent, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kossi","family":"Agbetiafa","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Institut Curie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Chauchet","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-7173","authenticated-orcid":false,"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Reims University Hospital, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Bonnet","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Li\u00e8ge University Hospital, Li\u00e8ge, Belgique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Fouillet","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Institut de Canc\u00e9rologie Lucien Neuwirth, Saint-Etienne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-7175","authenticated-orcid":false,"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Institut Bergonie, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Estaing University Hospital, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[{"name":"22Department of Pathology, Henri Mondor Hospital, Universit\u00e9 Paris-Est, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-4138","authenticated-orcid":false,"given":"Marie-C\u00e9cile","family":"Parrens","sequence":"additional","affiliation":[{"name":"23Department of Pathology, Bordeaux University Hospital, Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[{"name":"11Hematology Institute, University Hospital, Normandy University, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"18","key":"2023101015205591400_bib1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023101015205591400_bib2","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"De Leval","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2023101015205591400_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2023101015205591400_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"16","key":"2023101015205591400_bib5","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2023101015205591400_bib6","article-title":"Modified ESHAP regimen for relapsed\/refractory T cell lymphoma: a retrospective analysis","author":"Kogure","year":"2015;94(6):989-942","journal-title":"Ann Oncol"},{"issue":"4","key":"2023101015205591400_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"P\u00f6nisch","year":"2006","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"2023101015205591400_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023101015205591400_bib10","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023101015205591400_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann Hematol"},{"issue":"1","key":"2023101015205591400_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"51","key":"2023101015205591400_bib13","doi-asserted-by":"crossref","first-page":"85573","DOI":"10.18632\/oncotarget.10764","article-title":"Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study","volume":"7","author":"Reboursiere","year":"2016","journal-title":"Oncotarget"},{"issue":"10168","key":"2023101015205591400_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"2023101015205591400_bib15","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023101015205591400_bib16","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023101015205591400_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023101015205591400_bib18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.18215","article-title":"Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas","volume":"181","author":"Dumont","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"2023101015205591400_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023101015205591400_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ejh.13368","article-title":"Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas","volume":"104","author":"Wagner","year":"2020","journal-title":"Eur J Haematol"},{"issue":"23","key":"2023101015205591400_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V126.23.586.586","article-title":"The combination of brentuximab vedotin (Bv) and bendamustine (B) demonstrates marked activity in heavily treated patients with relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL): results of an international multi center phase I\/II experience","volume":"126","author":"Sawas","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2023101015205591400_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-016-2627-9","article-title":"Complete remission of refractory disseminated NK\/T cell lymphoma with brentuximab vedotin and bendamustine","volume":"95","author":"Poon","year":"2016","journal-title":"Ann Hematol"},{"key":"2023101015205591400_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"20","key":"2023101015205591400_bib24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2023101015205591400_bib25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2023101015205591400_bib26","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"27","key":"2023101015205591400_bib27","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023101015205591400_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023101015205591400_bib29","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023101015205591400_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed of refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023101015205591400_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-016-2877-6","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma\u2014not otherwise specified","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"2023101015205591400_bib32","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023101015205591400_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ejh.13568","article-title":"Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma","volume":"106","author":"Van de Wyngaert","year":"2021","journal-title":"Eur J Haematol"},{"issue":"21","key":"2023101015205591400_bib34","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2023101015205591400_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2023101015205591400_bib36","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomasFinal results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2023101015205591400_bib37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V120.21.797.797","article-title":"Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression","volume":"120","author":"Krathen","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2023101015205591400_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"19","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5733\/2083703\/blooda_adv-2022-008524-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5733\/2083703\/blooda_adv-2022-008524-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:27:50Z","timestamp":1696951670000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5733\/493432\/Salvage-therapy-with-brentuximab-vedotin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008524","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}